

AMENDMENTS TO THE CLAIMS

1. **(Original)** An angiotensin-converting enzyme containing medicine, of which action mechanism is release of GPI-anchored protein from the cell surface.
2. **(Original)** The medicine of claim 1 for preventing and curing prion-related diseases.
3. **(Original)** The medicine of claim 1 for preventing and curing bacterial infectious diseases.
4. **(Original)** The medicine of claim 1 for preventing and curing male infertility due to sperm abnormality.
5. **(Currently amended)** The medicine of ~~any claims 1 to 4~~ claim 1, wherein the angiotensin-converting enzyme is a mutant angiotensin-converting enzyme to which one or more amino acid mutation is introduced so that GPI-anchored protein releasing activity is maintained but peptidase activity is inactivated.
6. **(Original)** The medicine of claim 5, wherein the mutant angiotensin-converting enzyme has one or more amino acid substitution in the sequence of His Glu Met Gly.
7. **(Original)** The medicine of claim 6, wherein the mutant angiotensin-converting enzyme has Glu to Asp amino acid substitution in the sequence of His Glu Met Gly His.
8. **(Original)** A mutant angiotensin-converting enzyme to which amino acid mutation is introduced for inactivating peptidase activity.
9. **(Original)** The mutant angiotensin-converting enzyme of claim 8, which has one or more amino acid substitution in the sequence of His Glu Met Gly.

10. (Original) The mutant angiotensin-converting enzyme of claim 9, which has Glu to Asp amino acid substitution in the sequence of His Glu Met Gly His.

11. (New) The medicine of claim 2, wherein the angiotensin-converting enzyme is a mutant angiotensin-converting enzyme to which one or more amino acid mutation is introduced so that GPI-anchored protein releasing activity is maintained but peptidase activity is inactivated.

12. (New) The medicine of claim 3, wherein the angiotensin-converting enzyme is a mutant angiotensin-converting enzyme to which one or more amino acid mutation is introduced so that GPI-anchored protein releasing activity is maintained but peptidase activity is inactivated.

13. (New) The medicine of claim 4, wherein the angiotensin-converting enzyme is a mutant angiotensin-converting enzyme to which one or more amino acid mutation is introduced so that GPI-anchored protein releasing activity is maintained but peptidase activity is inactivated.

14. (New) The medicine of claim 11, wherein the mutant angiotensin-converting enzyme has one or more amino acid substitution in the sequence of His Glu Met Gly.

15. (New) The medicine of claim 12, wherein the mutant angiotensin-converting enzyme has one or more amino acid substitution in the sequence of His Glu Met Gly.

16. (New) The medicine of claim 13, wherein the mutant angiotensin-converting enzyme has one or more amino acid substitution in the sequence of His Glu Met Gly.

17. (New) The medicine of claim 14, wherein the mutant angiotensin-converting enzyme has Glu to Asp amino acid substitution in the sequence of His Glu Met Gly His.

18. (New) The medicine of claim 15, wherein the mutant angiotensin-converting enzyme has Glu to Asp amino acid substitution in the sequence of His Glu Met Gly His.

19. (New) The medicine of claim 16, wherein the mutant angiotensin-converting enzyme has Glu to Asp amino acid substitution in the sequence of His Glu Met Gly His.